SRx Health Solutions Warned by NYSE After Issuing 7.5M Shares Without Approval
SRx Health Solutions received an NYSE American warning letter for issuing approximately 7.5 million common shares upon Series A preferred conversions between December 31, 2025 and January 23, 2026 without obtaining required listing approval or shareholder consent for over 20% dilution. All preferred shares have since been converted or redeemed, leaving none outstanding.
1. Warning Letter Receipt
On February 18, 2026, SRx Health Solutions received a public warning letter from NYSE Regulation Staff citing non-compliance with Sections 301 and 713 of the NYSE American LLC Company Guide. The letter specifically addresses the issuance of common stock shares without requisite exchange approval or proper shareholder authorization.
2. Details of Share Issuance
Between December 31, 2025 and January 23, 2026, the company issued approximately 7.5 million common shares upon conversion of Series A Convertible Preferred Stock. NYSE rules require listing approval for additional share issuances and shareholder consent for issuances exceeding 20% of outstanding common shares, both of which were not secured in the proper form.
3. Filings and Shareholder Actions
SRx filed an application for listing approval on December 12, 2025 before any conversions occurred and obtained written shareholder consent on October 8, 2025 for potential dilution. The NYSE determined the proxy process used was deficient under its internal guidance, leading to the warning letter.
4. Current Status and Next Steps
As of February 12, 2026, all preferred shares have been either converted to common stock or redeemed, leaving no preferred shares outstanding. The company is evaluating corrective measures to satisfy NYSE requirements and avoid further disciplinary actions, including potential delisting.